7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis

Trial Profile

7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Arterial thrombosis; Catheter thrombosis; Venous thrombosis
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms EINSTEIN; Einstein Jr
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 24 Dec 2017 This trial has been completed in Finland (end date: 18 Dec 2017).
    • 20 Oct 2017 Planned End Date changed from 29 Dec 2017 to 2 Jan 2018.
    • 04 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top